Prospective deep phenotyping of choroideremia patients using multimodal structure-function approaches.


Journal

Eye (London, England)
ISSN: 1476-5454
Titre abrégé: Eye (Lond)
Pays: England
ID NLM: 8703986

Informations de publication

Date de publication:
Mar 2021
Historique:
received: 08 02 2020
accepted: 13 05 2020
revised: 13 05 2020
pubmed: 30 5 2020
medline: 6 7 2021
entrez: 30 5 2020
Statut: ppublish

Résumé

To investigate the retinal changes in choroideremia (CHM) patients to determine correlations between age, structure and function. Twenty-six eyes from 13 male CHM patients were included in this prospective longitudinal study. Participants were divided into <50-year (n = 8) and ≥50-year (n = 5) old groups. Patients were seen at baseline, 6-month, and 1-year visits. Optical coherence tomography (OCT), OCT angiography, and fundus autofluorescence were performed to measure central foveal (CFT) and subfoveal choroidal thickness (SCT), as well as areas of preserved choriocapillaris (CC), ellipsoid zone (EZ), and autofluorescence (PAF). Patients also underwent functional investigations including visual acuity (VA), contrast sensitivity (CS), colour testing, microperimetry, dark adaptometry, and handheld electroretinogram (ERG). Vision-related quality-of-life was assessed by using the NEI-VFQ-25 questionnaire. Over the 1-year follow-up period, progressive loss was detected in SCT, EZ, CC, PAF, and CFT. Those ≥50-years exhibited more structural and functional defects with SCT, EZ, CC, and PAF showing strong correlation with patient age (rho ≤ -0.47, p ≤ 0.02). CS and VA did not change over the year, but CS was significantly correlated with age (rho = -0.63, p = 0.001). Delayed to unmeasurable dark adaptation, decreased colour discrimination and no detectable ERG activity were observed in all patients. Minimal functional deterioration was observed over one year with a general trend of slower progression in the ≥50-years group. Quantitative structural parameters including SCT, CC, EZ, and PAF are most useful for disease monitoring in CHM. Extended follow-up studies are required to determine longitudinal functional changes.

Identifiants

pubmed: 32467628
doi: 10.1038/s41433-020-0974-1
pii: 10.1038/s41433-020-0974-1
pmc: PMC8027673
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

838-852

Subventions

Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 205174/Z/16/Z
Pays : United Kingdom
Organisme : Wellcome Trust (Wellcome)
ID : 205174/Z/16/Z

Références

Moosajee M, Ramsden SC, Black GC, Seabra MC, Webster AR. Clinical utility gene card for: choroideremia. Eur J Hum Genet. 2014;22:572.
doi: 10.1038/ejhg.2013.183
Mitsios A, Dubis AM, Moosajee M. Choroideremia: from genetic and clinical phenotyping to gene therapy and future treatments. Ther Adv Ophthalmol. 2018;10:2515841418817490.
pubmed: 30627697 pmcid: 6311551
Coussa RG, Traboulsi EI. Choroideremia: a review of general findings and pathogenesis. Ophthalmic Genet. 2012;33:57–65.
pubmed: 22017263 doi: 10.3109/13816810.2011.620056
Seabra MC, Brown MS, Goldstein JL. Retinal degeneration in choroideremia: deficiency of rab geranylgeranyl transferase. Science. 1993;259:377–81.
pubmed: 8380507 doi: 10.1126/science.8380507
MacLaren RE, Groppe M, Barnard AR, Cottriall CL, Tolmachova T, Seymour L, et al. Retinal gene therapy in patients with choroideremia: initial findings from a phase 1/2 clinical trial. Lancet. 2014;383:1129–37.
pubmed: 24439297 pmcid: 4171740 doi: 10.1016/S0140-6736(13)62117-0
Huckfeldt RM, Aleman TS, Doan T, Wen X-H, Weigel-DiFranco C, Chung DC, et al. Subfoveal gene augmentation therapy for choroideremia: one-year results from a Phase I/II trial of AAV2-hCHM. Investigative Ophthalmol Vis Sci. 2019;60:6401.
Moosajee M, Tracey-White D, Smart M, Weetall M, Torriano S, Kalatzis V, et al. Functional rescue of REP1 following treatment with PTC124 and novel derivative PTC-414 in human choroideremia fibroblasts and the nonsense-mediated zebrafish model. Hum Mol Genet. 2016;25:3416–31.
pubmed: 27329764 doi: 10.1093/hmg/ddw184
Abbouda A, Lim WS, Sprogyte L, Webster AR, Moosajee M. Quantitative and qualitative features of spectral-domain optical coherence tomography provide prognostic indicators for visual acuity in patients with choroideremia. Ophthalmic Surg Lasers Imaging Retin. 2017;48:711–6.
doi: 10.3928/23258160-20170829-05
Hagag AM, Gao SS, Jia Y, Huang D. Optical coherence tomography angiography: technical principles and clinical applications in ophthalmology. Taiwan J Ophthalmol. 2017;7:115–29.
pubmed: 28966909 pmcid: 5617355 doi: 10.4103/tjo.tjo_31_17
Abbouda A, Dubis AM, Webster AR, Moosajee M. Identifying characteristic features of the retinal and choroidal vasculature in choroideremia using optical coherence tomography angiography. Eye (Lond). 2018;32:563–71.
doi: 10.1038/eye.2017.242
Battaglia Parodi M, Arrigo A, MacLaren RE, Aragona E, Toto L, Mastropasqua R, et al. Vascular alterations revealed with optical coherence tomography angiography in patients with choroideremia. Retina 2019;39:1200–5.
pubmed: 29543633 doi: 10.1097/IAE.0000000000002118
Jolly JK, Edwards TL, Moules J, Groppe M, Downes SM, MacLaren RE. A qualitative and quantitative assessment of fundus autofluorescence patterns in patients with choroideremia. Invest Ophthalmol Vis Sci. 2016;57:4498–503.
pubmed: 27750291 doi: 10.1167/iovs.15-18362
Roberts MF, Fishman GA, Roberts DK, Heckenlively JR, Weleber RG, Anderson RJ, et al. Retrospective, longitudinal, and cross sectional study of visual acuity impairment in choroideraemia. Br J Ophthalmol. 2002;86:658–62.
pubmed: 12034689 pmcid: 1771148 doi: 10.1136/bjo.86.6.658
Renner AB, Kellner U, Cropp E, Preising MN, MacDonald IM, van den Hurk JA, et al. Choroideremia: variability of clinical and electrophysiological characteristics and first report of a negative electroretinogram. Ophthalmology. 2006;113:2066 e1–10.
doi: 10.1016/j.ophtha.2006.05.045
Hirakawa H, Iijima H, Gohdo T, Imai M, Tsukahara S. Progression of defects in the central 10-degree visual field of patients with retinitis pigmentosa and choroideremia. Am J Ophthalmol. 1999;127:436–42.
pubmed: 10218696 doi: 10.1016/S0002-9394(98)00408-5
Jolly JK, Xue K, Edwards TL, Groppe M, MacLaren RE. Characterizing the natural history of visual function in choroideremia using microperimetry and multimodal retinal imaging. Invest Ophthalmol Vis Sci. 2017;58:5575–83.
pubmed: 29084330 doi: 10.1167/iovs.17-22486
Jackson GR, Scott IU, Kim IK, Quillen DA, Iannaccone A, Edwards JG. Diagnostic sensitivity and specificity of dark adaptometry for detection of age-related macular degeneration. Invest Ophthalmol Vis Sci. 2014;55:1427–31.
pubmed: 24550363 pmcid: 3954002 doi: 10.1167/iovs.13-13745
Mangione CM, Lee PP, Gutierrez PR, Spritzer K, Berry S, Hays RD, et al. Development of the 25-item national eye institute visual function questionnaire. Arch Ophthalmol. 2001;119:1050–8.
pubmed: 11448327 doi: 10.1001/archopht.119.7.1050
Shao J, Zhong B. Last observation carry-forward and last observation analysis. Stat Med. 2003;22:2429–41.
pubmed: 12872300 doi: 10.1002/sim.1519
Kim S. ppcor: an R package for a fast calculation to semi-partial correlation coefficients. Commun Stat Appl Methods 2015;22:665–74.
pubmed: 26688802 pmcid: 4681537
Hagag AM, Wang J, Lu K, Harman G, Weleber RG, Huang D, et al. Projection-resolved optical coherence tomographic angiography of retinal plexuses in retinitis pigmentosa. Am J Ophthalmol. 2019;204:70–9.
pubmed: 30849344 pmcid: 7001722 doi: 10.1016/j.ajo.2019.02.034
Hagag AM, Pechauer AD, Liu L, Wang J, Zhang M, Jia Y, et al. OCT angiography changes in the 3 parafoveal retinal plexuses in response to hyperoxia. Ophthalmol Retin. 2018;2:329–36.
doi: 10.1016/j.oret.2017.07.022
Hagag AM, Mitsios A, Gill JS, Nunez Do Rio JM, Theofylaktopoulos V, Houston S, et al. Characterisation of microvascular abnormalities using OCT angiography in patients with biallelic variants in USH2A and MYO7A. Br J Ophthalmol. 2020;104:480–6.
pubmed: 31266775 doi: 10.1136/bjophthalmol-2019-314243
Hariri AH, Velaga SB, Girach A, Ip MS, Le PV, Lam BL, et al. Measurement and reproducibility of preserved ellipsoid zone area and preserved retinal pigment epithelium area in eyes with choroideremia. Am J Ophthalmol. 2017;179:110–7.
pubmed: 28499705 doi: 10.1016/j.ajo.2017.05.002
Spaide RF, Fujimoto JG, Waheed NK. Image artifacts in optical coherence tomography angiography. Retina. 2015;35:2163–80.
pubmed: 26428607 pmcid: 4712934 doi: 10.1097/IAE.0000000000000765
Seitz IP, Zhour A, Kohl S, Llavona P, Peter T, Wilhelm B, et al. Multimodal assessment of choroideremia patients defines pre-treatment characteristics. Graefes Arch Clin Exp Ophthalmol. 2015;253:2143–50.
pubmed: 25744334 doi: 10.1007/s00417-015-2976-4
Cameron JD, Fine BS, Shapiro I. Histopathologic observations in choroideremia with emphasis on vascular changes of the uveal tract. Ophthalmology. 1987;94:187–96.
pubmed: 3574884 doi: 10.1016/S0161-6420(87)33479-7
Mc CJ. The pathologic findings in two cases of choroideremia. Trans Am Acad Ophthalmol Otolaryngol. 1950;54:565–72.
Genead MA, Fishman GA. Cystic macular oedema on spectral-domain optical coherence tomography in choroideremia patients without cystic changes on fundus examination. Eye (Lond). 2011;25:84–90.
doi: 10.1038/eye.2010.157
Genead MA, McAnany JJ, Fishman GA. Topical dorzolamide for treatment of cystoid macular edema in patients with choroideremia. Retina. 2012;32:826–33.
pubmed: 21886018 pmcid: 3237959 doi: 10.1097/IAE.0b013e3182215ae9
Heon E, Alabduljalil T, McGuigan ID, Cideciyan AV, Li S, Chen S, et al. Visual function and central retinal structure in choroideremia. Invest Ophthalmol Vis Sci. 2016;57:OCT377–87.
pubmed: 27409497 doi: 10.1167/iovs.15-18421
Davson H. Electrophysiology of the retina: response to stimulation and the transduction process. In: Davson H, editor. Physiology of the Eye. 5 ed. London: Macmillan Press; 1990. p. 279–304.
Arden G. Measuring contrast sensitivity with gratings: A new simple technique for the early diagnosis of retinal and neurological disease. J Am Optom Assoc. 1979;50:35–9.
pubmed: 762375
Seitz IP, Jolly JK, Dominik Fischer M, Simunovic MP. Colour discrimination ellipses in choroideremia. Graefes Arch Clin Exp Ophthalmol. 2018;256:665–73.
pubmed: 29404760 doi: 10.1007/s00417-018-3921-0
Jolly JK, Groppe M, Birks J, Downes SM, MacLaren RE. Functional defects in color vision in patients with choroideremia. Am J Ophthalmol. 2015;160:822–31 e3.
pubmed: 26133251 doi: 10.1016/j.ajo.2015.06.018
Rudolph G, Preising M, Kalpadakis P, Haritoglou C, Lang GE, Lorenz B. Phenotypic variability in three carriers from a family with choroideremia and a frameshift mutation 1388delCCinsG in the REP-1 gene. Ophthalmic Genet. 2003;24:203–14.
pubmed: 14566650 doi: 10.1076/opge.24.4.203.17232
Hayakawa M, Fujiki K, Hotta Y, Ito R, Ohki J, Ono J, et al. Visual impairment and REP-1 gene mutations in Japanese choroideremia patients. Ophthalmic Genet. 1999;20:107–15.
pubmed: 10420196 doi: 10.1076/opge.20.2.107.2285
Dimopoulos IS, Tseng C, MacDonald IM. Microperimetry as an outcome measure in choroideremia trials: reproducibility and beyond. Invest Ophthalmol Vis Sci. 2016;57:4151–61.
pubmed: 27537265 doi: 10.1167/iovs.16-19338
Sarkar H, Mitsios A, Smart M, Skinner J, Welch AA, Kalatzis V, et al. Nonsense-mediated mRNA decay efficiency varies in choroideremia providing a target to boost small molecule therapeutics. Hum Mol Genet. 2019;28:1865–71.
pubmed: 30689859 pmcid: 6522067 doi: 10.1093/hmg/ddz028
Xue K, Jolly JK, Barnard AR, Rudenko A, Salvetti AP, Patricio MI, et al. Beneficial effects on vision in patients undergoing retinal gene therapy for choroideremia. Nat Med. 2018;24:1507–12.
pubmed: 30297895 pmcid: 7032956 doi: 10.1038/s41591-018-0185-5
Uji A, Balasubramanian S, Lei J, Baghdasaryan E, Al-Sheikh M, Sadda SR. Choriocapillaris imaging using multiple en face optical coherence tomography angiography image averaging. JAMA Ophthalmol. 2017;135:1197–204.
pubmed: 28983552 pmcid: 5710392 doi: 10.1001/jamaophthalmol.2017.3904
Gao SS, Patel RC, Jain N, Zhang M, Weleber RG, Huang D, et al. Choriocapillaris evaluation in choroideremia using optical coherence tomography angiography. Biomed Opt Express. 2017;8:48–56.
pubmed: 28101400 doi: 10.1364/BOE.8.000048
Wang Z, Camino A, Hagag AM, Wang J, Weleber RG, Yang P, et al. Automated detection of preserved photoreceptor on optical coherence tomography in choroideremia based on machine learning. J Biophotonics. 2018;11:e201700313.
doi: 10.1002/jbio.201700120
Camino A, Wang Z, Wang J, Pennesi ME, Yang P, Huang D, et al. Deep learning for the segmentation of preserved photoreceptors on en face optical coherence tomography in two inherited retinal diseases. Biomed Opt Express. 2018;9:3092–105.
pubmed: 29984085 pmcid: 6033582 doi: 10.1364/BOE.9.003092

Auteurs

Ahmed M Hagag (AM)

Moorfields Eye Hospital NHS Foundation Trust, London, UK.
UCL Institute of Ophthalmology, London, UK.

Andreas Mitsios (A)

Moorfields Eye Hospital NHS Foundation Trust, London, UK.
UCL Institute of Ophthalmology, London, UK.

Akshay Narayan (A)

UCL Institute of Ophthalmology, London, UK.

Alessandro Abbouda (A)

Moorfields Eye Hospital NHS Foundation Trust, London, UK.
UCL Institute of Ophthalmology, London, UK.

Andrew R Webster (AR)

Moorfields Eye Hospital NHS Foundation Trust, London, UK.
UCL Institute of Ophthalmology, London, UK.

Adam M Dubis (AM)

Moorfields Eye Hospital NHS Foundation Trust, London, UK.
UCL Institute of Ophthalmology, London, UK.

Mariya Moosajee (M)

Moorfields Eye Hospital NHS Foundation Trust, London, UK. m.moosajee@ucl.ac.uk.
UCL Institute of Ophthalmology, London, UK. m.moosajee@ucl.ac.uk.
Department of Ophthalmology, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK. m.moosajee@ucl.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH